Antidepressant discontinuation-related mania: Critical prospective observation and theoretical implications in bipolar disorder

被引:56
作者
Goldstein, TR
Frye, MA
Denicoff, KD
Smith-Jackson, E
Leverich, GS
Bryan, AL
Ali, SO
Post, RM
机构
[1] NIMH, Biol Psychiat Branch, Bethesda, MD 20892 USA
[2] Univ Colorado, Dept Clin Psychol, Boulder, CO 80309 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA
关键词
D O I
10.4088/JCP.v60n0811
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Development of manic symptoms on antidepressant discontinuation has primarily been reported in unipolar patients. This case series presents preliminary evidence for a similar phenomenon in bipolar patients. Method: Prospectively obtained life chart ratings of 73 bipolar patients at the National Institute of Mental Health were reviewed for manic episodes that emerged during antidepressant taper or discontinuation. Medical records were utilized as a corroborative resource. Six cases of antidepressant discontinuation-related mania were identified and critically evaluated. Results: All patients were taking conventional mood stabilizers. The patients were on antidepressant treatment a mean of 6.5 months prior to taper, which lasted an average of 20 days (range, 1-43 days). First manic symptoms emerged, on average, 2 weeks into the taper (range, 1-23 days). These 6 cases of antidepressant discontinuation-related mania involved 3 selective serotonin reuptake inhibitors (SSRIs), 2 tricyclic antidepressants (TCAs), and 1 serotonin-norepinephrine reuptake inhibitor. Mean length of the ensuing manic episode was 27.8 days (range, 12-49 days). Potential confounds such as antidepressant induction, phenomenological misdiagnosis of agitated depression, physiologic drug withdrawal syndrome, and course of illness were carefully evaluated and determined to be noncontributory. Conclusion: These 6 cases suggest a paradoxical effect whereby antidepressant discontinuation actually induces mania in spite of adequate concomitant mood-stabilizing treatment. These preliminary observations, if replicated in larger and controlled prospective studies, suggest the need for further consideration of the potential biochemical mechanisms involved so that new preventive treatment approaches can be assessed.
引用
收藏
页码:563 / 567
页数:5
相关论文
共 39 条
[1]  
AKIMOTO H, 1964, NEUROPSYCHOPHARMACOL, P552
[2]  
ALTSHULER LL, 1995, AM J PSYCHIAT, V152, P1130
[3]  
*AM PSYCH ASS, 1995, AM J PSYCHIAT S12, V151, P1
[4]  
Arana G.W., 1991, HDB PSYCHIAT DRUG TH
[5]   Trimipramine: A challenge to current concepts on antidepressives [J].
Berger, M ;
Gastpar, M .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1996, 246 (05) :235-239
[6]  
CECCHERININELLI A, 1993, AM J PSYCHIAT, V150, P165
[7]   ABRUPT DISCONTINUATION OF TRICYCLIC ANTI-DEPRESSANT DRUGS - EVIDENCE FOR NORADRENERGIC HYPERACTIVITY [J].
CHARNEY, DS ;
HENINGER, GR ;
STERNBERG, DE ;
LANDIS, H .
BRITISH JOURNAL OF PSYCHIATRY, 1982, 141 (OCT) :377-386
[8]   TRANSIENT MOOD ELEVATION ASSOCIATED WITH ANTIDEPRESSANT DRUG DECREASE [J].
CORRAL, M ;
SIVERTZ, K ;
JONES, BD .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1987, 32 (09) :764-767
[9]   Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p) [J].
Denicoff, KD ;
SmithJackson, EE ;
Disney, ER ;
Suddath, RL ;
Leverich, GS ;
Post, RM .
JOURNAL OF PSYCHIATRIC RESEARCH, 1997, 31 (05) :593-603
[10]  
DILSAVER SC, 1984, BIOL PSYCHIAT, V19, P237